Jazz to Present 30% pCR Data in Early HER2+ Breast Cancer
Jazz Pharmaceuticals will present one oral and six posters at AACR 2026, including NeoZanHER Phase 2 data showing a 30% pathologic complete response rate in early-stage HER2+ breast cancer after six weeks of zanidatamab. Presentations also feature mechanistic dual-binding HER2 analyses, JZP898 tumor-activated IFNα2b preclinical findings, and dordaviprone imipridone research.
1. AACR Presentation Line-Up
Jazz Pharmaceuticals and its partners will deliver one oral and six poster presentations at the AACR Annual Meeting in San Diego from April 17-22, showcasing research across its oncology portfolio, including studies on Ziihera® (zanidatamab), JZP898, and imipridone compounds.
2. NeoZanHER Phase 2 Breast Cancer Results
The NeoZanHER trial (NCT05035836) evaluated neoadjuvant zanidatamab monotherapy in early-stage HER2+ breast cancer patients. At six weeks, zanidatamab induced a statistically significant tumor size reduction and achieved a 30% pathologic complete response rate, with no new safety signals reported.
3. Preclinical Advances in JZP898 and Imipridones
Poster sessions will feature multi-omics analyses of zanidatamab’s dual, domain-specific HER2 binding, preclinical data demonstrating tumor-localized interferon signaling and immune engagement for JZP898, and activity profiles of dordaviprone and related imipridones in renal cell carcinoma and small-cell lung cancer models.